-
Je něco špatně v tomto záznamu ?
Activation of CVID patients' T cells with conventional antigens and superantigens
MB Fischer, I Hauber, H Eggenbauer, V Thon, J Lokaj, HM Wolf, JW Mannhalter, MM Eibl
Jazyk angličtina Země Švýcarsko
Grantová podpora
IZ1409
MZ0
CEP - Centrální evidence projektů
PubMed
8167691
Knihovny.cz E-zdroje
- MeSH
- aktivace lymfocytů * MeSH
- antigeny CD3 MeSH
- antigeny aplikace a dávkování MeSH
- běžná variabilní imunodeficience * imunologie MeSH
- enterotoxiny imunologie MeSH
- interferon gama biosyntéza MeSH
- interleukin-2 biosyntéza MeSH
- lidé MeSH
- receptory antigenů T-buněk MeSH
- Staphylococcus aureus imunologie MeSH
- superantigeny aplikace a dávkování MeSH
- T-lymfocyty * imunologie MeSH
- techniky in vitro MeSH
- Check Tag
- lidé MeSH
Defects in T cell function are known to be present in a subset of patients with CVID, but the true nature of these defects still has to be revealed. In prior studies we described that T cells from these patients show an impaired proliferative response following activation with recall antigens (E. coli, Tet. Tox., TBE and PPD). Gene expression of IL2 and IFN-gamma in patients' T cells following antigenic stimulation was significantly reduced compared to controls, while IL-2R transcripts were normal. To further characterize the defect we examined T cell responses to bacterial enterotoxins, collectively termed superantigens. Following stimulation with optimal (10 ng/ml p < 0.05) as well as suboptimal (1 ng/ml p < 0.0025) concentrations of staphylococcal enterotoxin A (SEA), proliferative response and cytokine release (IL-2 and IFNg) were significantly decreased in patients' T cells as compared to controls'. When patients' T cells were stimulated with staph. enterotox. C3 (SEC3) an even more pronounced difference between patients' and controls' T cells could be observed (10 ng/ml p < 0.002, 1 ng/ml p < 0.0005). Our data indicate that, in addition to the defect in antigen-induced T cell activation, T cells of CVID patients express a broader impairment in the interaction between the antigen presenting cell and the TCR.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13036488
- 003
- CZ-PrNML
- 005
- 20131125084929.0
- 007
- ta
- 008
- 131114s1993 sz f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)8167691
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Fischer, M.B. $u Institute of Immunology, University of Vienna, Austria.
- 245 10
- $a Activation of CVID patients' T cells with conventional antigens and superantigens / $c MB Fischer, I Hauber, H Eggenbauer, V Thon, J Lokaj, HM Wolf, JW Mannhalter, MM Eibl
- 520 9_
- $a Defects in T cell function are known to be present in a subset of patients with CVID, but the true nature of these defects still has to be revealed. In prior studies we described that T cells from these patients show an impaired proliferative response following activation with recall antigens (E. coli, Tet. Tox., TBE and PPD). Gene expression of IL2 and IFN-gamma in patients' T cells following antigenic stimulation was significantly reduced compared to controls, while IL-2R transcripts were normal. To further characterize the defect we examined T cell responses to bacterial enterotoxins, collectively termed superantigens. Following stimulation with optimal (10 ng/ml p < 0.05) as well as suboptimal (1 ng/ml p < 0.0025) concentrations of staphylococcal enterotoxin A (SEA), proliferative response and cytokine release (IL-2 and IFNg) were significantly decreased in patients' T cells as compared to controls'. When patients' T cells were stimulated with staph. enterotox. C3 (SEC3) an even more pronounced difference between patients' and controls' T cells could be observed (10 ng/ml p < 0.002, 1 ng/ml p < 0.0005). Our data indicate that, in addition to the defect in antigen-induced T cell activation, T cells of CVID patients express a broader impairment in the interaction between the antigen presenting cell and the TCR.
- 590 __
- $a bohemika - dle Pubmed
- 650 02
- $a antigeny $x aplikace a dávkování $7 D000941
- 650 02
- $a antigeny CD3 $7 D017252
- 650 12
- $a běžná variabilní imunodeficience $x imunologie $7 D017074
- 650 02
- $a enterotoxiny $x imunologie $7 D004768
- 650 02
- $a lidé $7 D006801
- 650 02
- $a interferon gama $x biosyntéza $7 D007371
- 650 02
- $a interleukin-2 $x biosyntéza $7 D007376
- 650 12
- $a aktivace lymfocytů $7 D008213
- 650 02
- $a receptory antigenů T-buněk $7 D011948
- 650 02
- $a Staphylococcus aureus $x imunologie $7 D013211
- 650 02
- $a superantigeny $x aplikace a dávkování $7 D018089
- 650 12
- $a T-lymfocyty $x imunologie $7 D013601
- 650 _2
- $a techniky in vitro $7 D066298
- 700 1_
- $a Hauber, I.
- 700 1_
- $a Eggenbauer, H.
- 700 1_
- $a Thon, Vojtěch $7 xx0060109
- 700 1_
- $a Lokaj, Jindřich, $d 1939- $7 jk01072349
- 700 1_
- $a Wolf, H.M.
- 700 1_
- $a Mannhalter, J.W.
- 700 1_
- $a Eibl, M.M.
- 773 0_
- $t Immunodeficiency $x 1067-795X $g Roč. 4, č. 1-4 (1993), s. 15-16 $p Immunodeficiency $w MED00182409
- 910 __
- $a ABA008 $y 4 $z 0
- 990 __
- $a 20131114140128 $b ABA008
- 991 __
- $a 20131125085602 $b ABA008
- 999 __
- $a ok $b bmc $g 1000794 $s 834973
- BAS __
- $a 3
- BMC __
- $a 1993 $b 4 $c 1-4 $d 15-16 $x MED00182409 $i 1067-795X $m Immunodeficiency $n Immunodeficiency
- GRA __
- $a IZ1409 $p MZ0
- LZP __
- $a NLK 2013-11/lpbo